|  |  |  |
| --- | --- | --- |
| Macintosh HD:Users:bilodeau:Desktop:logos:template 2017:un.emf | Macintosh HD:Users:bilodeau:Desktop:logos:template 2017:unep-old.emf | **CBD** |

|  |  |
| --- | --- |
| CBD_logo_CMYK_black [Converted] | Distr.  GENERAL  CBD/SBI/2/13  27 May 2018  ORIGINAL: ENGLISH |

SUBSIDIARY BODY ON IMPLEMENTATION

Second meeting

Montreal, Canada, 9-13 July 2018

Item 13 of the provisional agenda[[1]](#footnote-1)\*

**Monitoring and reporting (Article 33) and assessment and review of the effectiveness of the CARTAGENA Protocol ON BIOSAFETY (Article 35)**

*Note by the Executive Secretary*

BACKGROUND

1. Article 33 of the Cartagena Protocol on Biosafety requires Parties to monitor the implementation of their obligations under the Protocol and to report, at intervals to be determined by the Conference of the Parties serving as the meeting of the Parties to the Protocol, on measures taken to implement the Protocol.
2. Article 35 of the Cartagena Protocol requires the Conference of the Parties serving as the meeting of the Parties to the Cartagena Protocol on Biosafety (COP-MOP) to undertake, five years after the entry into force of the Protocol and at least every five years thereafter, an evaluation of the effectiveness of the Protocol, including an assessment of its procedures and annexes.
3. The Strategic Plan for the Cartagena Protocol on Biosafety for the period 2011-2020 (Strategic Plan)[[2]](#footnote-2) was adopted by COP-MOP in 2010 through its [decision BS-V/16](http://bch.cbd.int/protocol/decisions/?decisionID=12329).The Parties to the Protocol decided that a mid‑term evaluation of the Strategic Plan would be carried out five years after its adoption in conjunction with the third assessment and review of the effectiveness of the Protocol, at the eighth meeting of COP-MOP.
4. The present note aims at assisting the Subsidiary Body on Implementation in considering (a) a draft revised format for the fourth national report under the Cartagena Protocol on Biosafety, and (b) a process for the upcoming fourth assessment and review of the effectiveness of the Cartagena Protocol and the final evaluation of the Strategic Plan. Section I provides a summary of the monitoring and reporting process leading to the drafting of the revised format for the fourth national report under the Cartagena Protocol as contained in the annex. Section II provides a summary of the process undertaken for the third assessment and review of the Protocol and the mid-term evaluation of the Strategic Plan, and a possible way forward. Section III contains two sets of suggested recommendations of the Subsidiary Body on Implementation to the ninth meeting of the Conference of the Parties serving as the meeting of the Parties to the Cartagena Protocol with regard to (a) monitoring and reporting and (b) assessment and review.
5. **MONITORING AND REPORTING: Draft revised format for the fourth national report under the Cartagena Protocol on Biosafety**
6. In its decision [BS-I/9](https://www.cbd.int/decision/mop/default.shtml?id=8291), the meeting of the Parties to the Cartagena Protocol requested Parties to submit their reports every four years, twelve months prior to the meeting of the Parties to the Protocol at which the reports would be considered. To date, Parties to the Protocol have been requested to submit national reports as follows: (a) an interim national report in 2005 (decision BS-I/9); (b) a first national report in 2007 (decision [BS-III/14](https://www.cbd.int/decision/mop/default.shtml?id=11071)); (c) a second national report in 2011 (decision [BS-V/14](https://www.cbd.int/decision/mop/default.shtml?id=12327)); and (d) a third national report in 2015 (decision [BS-VII/14](https://www.cbd.int/doc/decisions/mop-07/mop-07-dec-14-en.pdf)).
7. The format for the third national report, which was welcomed by Parties in decision BS‑VII/14, was the first format to include, in addition to questions related to the implementation of provisions of the Protocol, questions related to the indicators of the [Strategic Plan for the Cartagena Protocol on Biosafety for the period 2011-2020](https://bch.cbd.int/protocol/issues/cpb_stplan.shtml) to facilitate the third assessment and review of the effectiveness of the Protocol and the mid-term evaluation of the Strategic Plan.[[3]](#footnote-3)
8. Following the third assessment and review of the Protocol and the mid-term evaluation of the Strategic Plan, the Conference of the Parties serving as the meeting of the Parties to the Protocol requested the Executive Secretary to develop a revised format for the fourth national report with a view to ensuring that complete and accurate information was captured while striving to ensure the applicability of the baseline information, as established in decision [BS-VI/15](https://www.cbd.int/decisions/?id=13248),[[4]](#footnote-4) for review by the Subsidiary Body on Implementation and for consideration at the ninth meeting of the Parties to the Protocol, in particular by:
   * 1. Improving the formulation of questions for their clarity, providing further explanation where necessary (decision [CP-VIII/14](https://www.cbd.int/doc/decisions/mop-08/mop-08-dec-14-en.pdf));
     2. Eliminating the redundancy observed in the questions used for the third national report (decision CP-VIII/14);
     3. Adding questions that address mainstreaming biosafety into national biodiversity strategies and action plans, other policies and legislation (decision CP-VIII/14);
     4. Aligning the language of the relevant questions in the draft format with the adopted operational definitions of the terms “unintentional transboundary movement” and “illegal transboundary movement” (decision [CP-VIII/16](https://www.cbd.int/doc/decisions/mop-08/mop-08-dec-16-en.pdf)).
9. Further to addressing the specific issues requested in the decisions, questions related to liability and redress have been included in the proposed draft revised reporting format in the light of the entry into force of the Nagoya-Kuala Lumpur Supplementary Protocol on Liability and Redress. The additional questions in the draft revised reporting format would enable Parties to provide information for the review of the effectiveness of the Supplementary Protocol.[[5]](#footnote-5)
10. Accordingly, the Secretariat has prepared a draft revised format for the fourth national report, as presented in the annex. Information for cross-referencing the questions in the draft revised format is available as document CBD/SBI/2/INF/22.
11. The [Global Environment Facility](https://www.thegef.org/) has provided financial support to eligible Parties to assist in the preparation and submission of their second and third national reports. This support was welcomed by the meeting of the Parties to the Cartagena Protocol (e.g. decision CP-VIII/14, para. 2) and has played an important role in the submission of national reports under the Protocol as recognized in decision BS‑VI/14. The Subsidiary Body on Implementation may thus wish to recommend to the meeting of the Parties to the Cartagena Protocol to recommend to the Conference of the Parties to the Convention that, in providing guidance to the financial mechanism, it invite the Global Environment Facility to make financial resources available with a view to enabling eligible Parties to prepare and submit their fourth national reports.
12. **ASSESSMENT AND REVIEW and FINAL evaluation of the strategic plan for the Cartagena Protocol on Biosafety**
    * 1. **Summary of the process undertaken for the third assessment and review and mid-term evaluation of the strategic plan for the Cartagena Protocol on Biosafety**
13. In [decision BS-VII/3](http://bch.cbd.int/protocol/decisions/?decisionID=13350), the COP-MOP set out a process for the third assessment and review of the Protocol in conjunction with the mid-term evaluation of the Strategic Plan whereby it requested the Subsidiary Body on Implementation to review the information gathered and analysed by the Executive Secretary with input from the Compliance Committee and the Liaison Group on Capacity-Building.
14. The Secretariat undertook an in-depth comparative analysis of the information submitted by Parties through their third national reports[[6]](#footnote-6) against the baseline data obtained during the second national reporting cycle.[[7]](#footnote-7) To facilitate the compilation, aggregation and analysis of the available data, the Secretariat developed an online national report analyzer tool, which is available on the Biosafety Clearing-House[[8]](#footnote-8) for the comparison of data in the third national reports against the baseline. Additionally, where appropriate, data obtained from the Biosafety-Clearing House was used in the analysis of some indicators and compared with similar data used in the analysis during the second reporting cycle.
15. At its thirteenth meeting, the Compliance Committee provided its input into the third assessment and review of the Protocol and the mid-term evaluation of the Strategic Plan in response to the request contained in BS-VII/3.[[9]](#footnote-9) The scope of the Compliance Committee’s input focused on:
    * + - 1. The progress made with respect to Operational Objective 3.1 of the Strategic Plan that refers to the strengthening of the mechanisms for achieving compliance;
          2. The extent to which information in the Biosafety-Clearing House is reliable and up to date;
          3. The experience gained by the Committee in implementing its supportive role as specified in [decision BS-V/1](http://bch.cbd.int/protocol/decisions/?decisionID=12314).
16. At its eleventh meeting, the Liaison Group prepared its contribution to the third assessment and review and mid-term evaluation of the Strategic Plan. The Liaison Group examined a comparative analysis prepared by the Secretariat[[10]](#footnote-10) of the status and trends in the implementation of each of the operational objectives of the Strategic Plan except Operational Objective 3.1 on compliance, on the basis of the indicators of the Strategic Plan.[[11]](#footnote-11)
17. The Subsidiary Body on Implementation undertook a review of the information and conclusions provided by the Liaison Group and Compliance Committee, and submitted its findings and recommendations to the COP-MOP at its eighth meeting.
18. In decision CP VIII/15, COP-MOP welcomed the work and contribution from the different steps in the process for the third assessment and review of the Protocol and mid-term evaluation of the Strategic Plan, and requested the Compliance Committee to continue providing inputs to the final evaluation of the Strategic Plan. In the same decision, COP-MOP called upon Parties, for the remaining period of the Strategic Plan, to consider prioritizing the operational objectives relating to the development of biosafety legislation, risk assessment, risk management, detection and identification of living modified organisms, and public awareness, education and training in view of their critical importance in facilitating the implementation of the Protocol.
    * 1. **Possible way forward for the fourth assessment and review and final evaluation of the Strategic Plan for the Cartagena Protocol on Biosafety (2011-2020)**
19. Building on the positive experience resulting from the process described in section II above, a similar process may be considered as a way forward for undertaking the fourth assessment and review of the Cartagena Protocol in combination with the final evaluation of the Strategic Plan.
20. The process would comprise the following steps:
21. The Secretariat would analyse and synthesize information on the implementation of the Protocol using the fourth national reports as a primary source, the Biosafety Clearing-House and, where appropriate, additional data to facilitate the process, and compare the information against the baseline;
22. The Liaison Group on Capacity-Building and the Compliance Committee would contribute, in a complementary and non-duplicative manner, to the fourth assessment and review of the Cartagena Protocol and the final evaluation of the Strategic Plan;
23. The Subsidiary Body on Implementation would consider the contributions by the Liaison Group and the Compliance Committee, and would submit its findings and recommendations for consideration by the COP-MOP at its tenth meeting.
24. **SUGGESTED recommendations**
25. **Monitoring and Reporting (article 33)**
26. The Subsidiary Body on Implementation may wish to recommend that the Conference of the Parties serving as the meeting of the Parties to the Cartagena Protocol at its ninth meeting adopt a decision along the following lines:

*The Conference of the Parties serving as the meeting of the Parties to the Cartagena Protocol on Biosafety*

1. *Adopts* the reporting format annexed hereto and requests Parties to use it for the fourth national report on the implementation of the Cartagena Protocol on Biosafety;
2. *Invites* Parties to prepare their reports through a consultative process involving all relevant national stakeholders, as appropriate;
3. *Encourages* Parties to respond to all questions in the reporting format, and *stresses* the importance of the timely submission of fourth national reports in order to facilitate the fourth assessment and review of the effectiveness of the Cartagena Protocol and the final evaluation of the Strategic Plan for the Cartagena Protocol on Biosafety for the period 2011-2020;[[12]](#footnote-12)
4. *Requests* Parties and *invites* other Governments to submit to the Secretariat their fourth national report on the implementation of the Cartagena Protocol on Biosafety:
   * 1. In an official language of the United Nations;
     2. Twelve months prior to the tenth meeting of the Conference of the Parties serving as the meeting of the Parties to the Protocol, which will consider the report;
     3. Preferably online through the Biosafety Clearing-House, or offline using the appropriate form that will be made available by the Secretariat for this purpose, duly signed by the national focal point for the Cartagena Protocol;
5. *Recommends* to the Conference of the Parties, in adopting guidance to the financial mechanism, that it invite the Global Environment Facility to make available, in a timely manner, financial resources to eligible Parties to facilitate the preparation and submission of their fourth national reports under the Protocol.
6. **Assessment and Review (article 35)**
7. The Subsidiary Body on Implementation may wish to recommend that the Conference of the Parties serving as the meeting of the Parties to the Cartagena Protocol at its ninth meeting adopt a decision along the following lines:

*The Conference of the Parties serving as the meeting of the Parties to the Cartagena Protocol on Biosafety*

* 1. *Reiterates* its invitation to Parties, for the remaining period of the Strategic Plan for the Cartagena Protocol on Biosafety for 2011-2020, to consider prioritizing the operational objectives relating to the development of biosafety legislation, risk assessment, detection and identification of living modified organisms, and public awareness in view of their critical importance in facilitating the implementation of the Protocol.
  2. *Decides* that the fourth assessment and review of the Cartagena Protocol will be combined with the final evaluation of the Strategic Plan for the Cartagena Protocol for the period 2011-2020.
  3. *Requests* the Executive Secretary:
     1. To continue making improvements to the online national report analyzer tool to facilitate the compilation, aggregation and analysis of the data in the fourth national reports and other sources against related baseline data that was obtained during the second national reporting cycle;
     2. To analyse and synthesize information on the implementation of the Protocol using the fourth national reports as a primary source, the Biosafety Clearing-House and, where appropriate, additional data to facilitate the fourth assessment and review of the Protocol in conjunction with the final evaluation of the Strategic Plan, and make this information available to the Liaison Group on Capacity-Building and the Compliance Committee.
  4. *Also requests* the Liaison Group on Capacity-Building and the Compliance Committee, working in a complementary and non-duplicative manner, to contribute to the fourth assessment and review of the Cartagena Protocol and the final evaluation of the Strategic Plan, and to submit their conclusions for consideration by the Subsidiary Body on Implementation.
  5. *Further requests* the Subsidiary Body on Implementation, at its third meeting, to consider the information provided and conclusions reached by the Liaison Group and the Compliance Committee, and to submit its findings and recommendations to the Conference of the Parties serving as the meeting of the Parties to the Cartagena Protocol at its tenth meetingwith a view to facilitating the fourth assessment and review of the Cartagena Protocol and the final evaluation of the Strategic Plan for the Cartagena Protocol on Biosafety for the period 2011-2020.

*Annex*

**Draft revised format for the fourth national report under the Cartagena Protocol on Biosafety**

**Origin of the report**

|  |  |
| --- | --- |
| 1. **Country:** | **[ Type your text here ]** |
| *Contact person submitting the report* |  |
| 1. Name: | **[ Type your text here ]** |
| 1. Title: | **[ Type your text here ]** |
| 1. Organization: | **[ Type your text here ]** |
| 1. Mailing address: | **[ Type your text here ]** |
| 1. Telephone: | **[ Type your text here ]** |
| 1. Fax: | **[ Type your text here ]** |
| 1. E-mail: | **[ Type your text here ]** |
| 1. Organizations/stakeholders who were consulted or participated in the preparation of this report: | **[ Type your text here ]** |
| *Submission* |  |
| 1. Date of submission: | **[ day / month / year ]** |
| 1. Time period covered by this report: | **From [month / year] to [month / year]** |

Signature of the reporting officer[[13]](#footnote-13) \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| 1. If your country is not a Party to the Cartagena Protocol on Biosafety (CPB), is there any national process in place towards becoming a Party? | | | Yes  No | |
| 1. Here you may provide further details:   [ Type your text here ] | | | | |
| **Article 2 – General provisions**  *Article 2 requires each Party to take the necessary and appropriate legal, administrative and other measures to implement its obligations under the Protocol.* | | | | |
| 1. Has your country introduced the necessary measures for the implementation of the Protocol? | | | National measures are fully in place  National measures are partially in place  Only temporary measures have been introduced  Only draft measures exist  No measures have yet been taken | |
| 1. Which specific instruments are in place for the implementation of national biosafety measures? | | | One or more national biosafety laws  One or more national biosafety regulations  One or more sets of biosafety guidelines  Other laws, regulations or guidelines that indirectly apply to biosafety  No instruments are in place | |
| 1. Has your country undertaken initiatives to mainstream biosafety into national biodiversity strategies and action plans, other policies and legislation? | | | Yes: [Please specify]  No | |
| 1. Has your country established a mechanism for budget allocations for the operation of its national biosafety measures? | | | Yes  No | |
| 1. Does your country have permanent staff to administer functions directly related to biosafety? | | | Yes  No | |
| 1. If you answered *Yes* to question 18, how many permanent staff members are in place whose functions are directly related to the national biosafety framework? | | | 1 to 4  5 to 9  10 or more  *Is this number adequate:  Yes  No* | |
| 1. Here you may provide further details on the implementation of Article 2 in your country:   [ Type your text here ] | | | | |
| **Article 5 – Pharmaceuticals** | | | | |
| 1. Does your country regulate the transboundary movement, handling or use of LMOs which are pharmaceuticals to humans? | | | Yes  No | |
| 1. Here you may provide further details on the implementation of Article 5 in your country:   [ Type your text here ] | | | | |
| **Article 6 – Transit and Contained use** | | | | |
| 1. Does your country regulate the transit of LMOs? | | | Yes  No | |
| 1. Does your country regulate the contained use of LMOs? | | | Yes  No | |
| 1. Has your country taken a decision concerning the import of LMOs for contained use? | | | Yes  No | |
| 1. Here you may provide further details on the implementation of Article 6 in your country:   [ Type your text here ] | | | | |
| **Articles 7 to 10: Advance Informed Agreement (AIA) and  intentional introduction of LMOs into the environment** | | | | |
| 1. Has your country established legal requirements for exporters under its jurisdiction to notify in writing the competent national authority of the Party of import prior to the intentional transboundary movement of an LMO that falls within the scope of the AIA procedure? | | | Yes  No | |
| 1. When acting as the Party of export, has your country established legal requirements for the accuracy of information contained in the notification provided by the exporter? | | | Yes  No | |
| 1. In the current reporting period, has your country received a notification regarding intentional transboundary movements of LMOs for intentional introduction into the environment? | | | Yes  No | |
| 1. If you answered *Yes* to question 29, did the notification(s) contain complete information (at a minimum the information specified in Annex I of the Cartagena Protocol on Biosafety)? | | | Yes, always  In some cases only  No | |
| 1. If you answered *Yes* to question 29, has your country acknowledged receipt of the notification(s) to the notifier within ninety days of receipt? | | | Yes, always  In some cases only  No | |
| 1. If you answered *Yes* to question 29, has your country informed both the notifier(s) and the BCH of its decision(s)? | | | Yes, always  In some cases only  No | |
| 1. In the current reporting period, has your country taken a decision in response to the notification(s) regarding intentional transboundary movements of LMOs for intentional introduction into the environment? | | | Yes  No | |
| 1. If you answered *Yes* to question 33, how many LMOs has your country approved for import for intentional introduction into the environment? | | | None  1 to 4  5 to 9  10 or more | |
| 1. If you answered *under question 34* that *LMOs were approved*, have all these LMOs actually been imported into your country? | | | Yes, always  In some cases only  No | |
| 1. If you answered *Yes* to question 34, what percentage of your country’s decisions fall into the following categories? | | | [ %] Approval of the import/use of the LMO(s) without conditions  [ %] Approval of the import/use of the LMO(s) with conditions  [ %] Prohibition of the import/use of the LMO(s)  [ %] Request for additional relevant information  [ %] Inform the notifier that the period for communicating the decision has been extended | |
| 1. If you answered *under question 36* that your country has taken a decision to *approve the import with conditions* or to *prohibit the import*, were the reasons provided? | | | Yes, always  In some cases only  No | |
| 1. Here you may provide further details on the implementation of Articles 7-10 in your country, including measures in case of lack of scientific certainty on potential adverse effects of LMOs for intentional introduction to the environment:   [ Type your text here ] | | | | |
| **Article 11 – Procedure for living modified organisms  intended for direct use as food or feed, or for processing (LMOs-FFP)** | | | | |
| 1. Does your country have law(s), regulation(s) or administrative measures for decision-making regarding domestic use, including placing on the market, of LMOs that may be subject to transboundary movement for direct use as food or feed, or for processing? | Yes  No | | | |
| 1. Has your country established legal requirements for the accuracy of information to be provided by the applicant regarding the domestic use, including placing on the market, of LMOs that may be subject to transboundary movement for direct use as food or feed, or for processing? | Yes  No | | | |
| 1. In the current reporting period, how many decisions has your country taken regarding domestic use, including placing on the market, of LMOs that may be subject to transboundary movement for direct use as food or feed, or for processing? | None  1 to 4  5 to 9  10 or more | | | |
| 1. Does your country have law(s), regulation(s) or administrative measures for decision-making regarding the import of LMOs for direct use as food or feed, or for processing? | Yes  No | | | |
| 1. In the current reporting period, how many decisions has your country taken regarding the import of LMOs for direct use as food or feed, or for processing? | None  1 to 4  5 to 9  10 or more | | | |
| 1. Here you may provide further details on the implementation of Article 11 in your country, including measures in case of lack of scientific certainty on potential adverse effects of LMOs that may be subject to transboundary movement for direct use as food or feed, or for processing:   [ Type your text here ] | | | | |
| **Article 12 – Review of decision** | | | | |
| 1. Has your country established a mechanism for the review and change of a decision regarding an intentional transboundary movement of LMOs? | Yes  No | | | |
| 1. In the current reporting period, has your country reviewed and/or changed a decision regarding an intentional transboundary movement of an LMO? | Yes  No | | | |
| 1. If you answered *Yes* to question 46, how many decisions were reviewed and/or changed? | 1 to 4  5 to 9  10 or more | | | |
| 1. If you answered *Yes* to question 46, were any of the reviews triggered by a request from the Party of export or the notifier? | Yes  No | | | |
| 1. If you answered *Yes* to question 48, did your country provide a response within ninety days setting out the reasons for the decision? | Yes, always  In some cases only  No | | | |
| 1. If you answered *Yes* to question 46, were any of the reviews initiated by your country as the Party of import? | Yes  No | | | |
| 1. If you answered *Yes* to question 50, did your country, within thirty days, inform both the notifier and the BCH and set out the reasons for the decision? | Yes, always  In some cases only  No | | | |
| 1. Here you may provide further details on the implementation of Article 12 in your country:   [ Type your text here ] | | | | |
| **Article 13 – Simplified procedure** | | | | |
| 1. Has your country established a mechanism for the application of the simplified procedure regarding an intentional transboundary movement of LMOs? | Yes  No | | | |
| 1. In the current reporting period, has your country applied the simplified procedure? | Yes  No | | | |
| 1. If you answered *Yes* to question 54, for how many LMOs has your country applied the simplified procedure? | None  1 to 5  5 or more | | | |
| 1. If you answered *Yes* to question 54, has your country informed the Parties through the BCH of the cases where the simplified procedure was applied? | Yes, always  In some cases only  No | | | |
| 1. Here you may provide further details on the implementation of Article 13 in your country:   [ Type your text here ] | | | | |
| **Article 14 – Bilateral, regional and multilateral agreements and arrangements** | | | | |
| 1. How many bilateral, regional or multilateral agreements or arrangements relevant to biosafety has your country established with other Parties/non-Parties? | None  1 to 4  5 to 9  10 or more | | | |
| 1. If you answered *under question 58* that *agreements or arrangements were established*, please provide a brief description of their scope and objective:   [ Type your text here ] | | | | |
| 1. Here you may provide further details on the implementation of Article 14 in your country:   [ Type your text here ] | | | | |
| **Articles 15 & 16 – Risk Assessment and Risk Management** | | | | |
| 1. Does the domestic regulatory framework of your country require risk assessments of LMOs to be conducted? | Yes  No | | | |
| 1. If you answered *Yes* to question 61, in respect of which LMOs does the requirement apply (select all that apply)? | For imports of LMOs for intentional introduction into the environment  For exports of LMOs for intentional introduction into the environment  For imports of LMOs intended for direct use as food or feed, or for processing  For decisions regarding domestic use, including placing on the market, of LMOs that may be subject to transboundary movements for direct use as food or feed, or for processing  For imports of LMOs for contained use  For exports of LMOs for contained use  Other: [Please specify] | | | |
| 1. Has your country established a mechanism to conduct risk assessments prior to taking decisions regarding LMOs? | Yes  No | | | |
| 1. If you answered *Yes* to question 63, does the mechanism include procedures to identify and/or train national experts to conduct risk assessments? | Yes  No | | | |
| *Capacity building in risk assessment or risk management* | | | | |
| 1. How many people in your country have been trained in risk assessment, monitoring, management and control of LMOs? | | | | |
| 1. Risk assessment: | | None  1 to 9  10 to 49  50 to 99  100 or more  *Is this number adequate:  Yes  No* | | |
| 1. Risk management: | | None  1 to 9  10 to 49  50 to 99  100 or more  *Is this number adequate:  Yes  No* | | |
| 1. Monitoring: | | None  1 to 9  10 to 49  50 to 99  100 or more  *Is this number adequate:  Yes  No* | | |
| 1. Is your country using training material and/or technical guidance for training in risk assessment and risk management of LMOs? | | Yes  No | | |
| 1. If you answered *Yes* to question 66, is your country using the “Manual on Risk Assessment of LMOs” (developed by the CBD Secretariat) for training in risk assessment? | | Yes  No | | |
| 1. If you answered *Yes* to question 66, is your country using the “Guidance on Risk Assessment of LMOs” (developed by the Online Forum and the AHTEG on Risk Assessment and Risk Management) for training in risk assessment? | | Yes  No | | |
| 1. Does your country have specific needs for further guidance on specific topics of risk assessment of LMOs? | | Yes: [Please specify]  No | | |
| 1. Does your country have the capacity to detect, identify, assess the risk of and/or monitor LMOs or specific traits that may have adverse effects on the conservation and sustainable use of biological diversity, taking into account risks to human health? | | | | |
| 1. Detect: | | Yes  No | | |
| 1. Identify: | | Yes  No | | |
| 1. Assess the risk: | | Yes  No | | |
| 1. Monitor: | | Yes  No | | |
| *Conducting risk assessment or risk management* | | | |
| 1. Has your country adopted or used any guidance documents for the purpose of conducting risk assessment or risk management, or for evaluating risk assessment reports submitted by notifiers? | | | |
| 1. Risk assessment: | | Yes  No | |
| 1. Risk management: | | Yes  No | |
| 1. If you answered *Yes* to question 71, is your country using the “Guidance on Risk Assessment of LMOs” (developed by the Online Forum and the AHTEG on Risk Assessment and Risk Management) for conducting risk assessment or risk management, or for evaluating risk assessment reports submitted by notifiers? | | Yes  No | |
| 1. Has your country adopted common approaches or methodologies to risk assessment in coordination with other countries? | | Yes  No | |
| 1. Has your country cooperated with other Parties with a view to identifying LMOs or specific traits that may have adverse effects on the conservation and sustainable use of biological diversity? | | Yes  No | |
| 1. In the reporting period, has your country conducted any kind of risk assessment of LMOs, including for contained use, field trials, commercial purposes, direct use as food, feed, or for processing? | | Yes  No | |
| 1. If you answered *Yes* to question 75, how many risk assessments were conducted? | | 1 to 4  5 to 9  10 or more | |
| 1. If you answered *Yes* to question 75, please indicate the scope of the risk assessments (select all that apply): | | LMOs for contained use (in accordance with article 3)  LMOs for intentional introduction into the environment for experimental testing or field trials  LMOs for intentional introduction into the environment for commercial purposes  LMOs for direct use as food  LMOs for direct use as feed  LMOs for processing  Other: [Please specify] | |
| 1. If you answered *Yes* to question 75, were risk assessments conducted for all decisions taken on LMOs for intentional introduction into the environment or on domestic use of LMOs that may be subject to transboundary movement for direct use as food or feed, or for processing? | | Yes, always  In some cases only  No | |
| 1. Has your country established appropriate mechanisms, measures and strategies to regulate and manage risks identified in the risk assessment of LMOs? | | Yes  No | |
| 1. Has your country taken appropriate measures to prevent unintentional transboundary movements of LMOs, including such measures as requiring a risk assessment to be carried out prior to the first release of a LMO? | | Yes  No | |
| 1. Has your country taken measures to ensure that any LMO, whether imported or locally developed, undergoes an appropriate period of observation that is commensurate with its life-cycle or generation time before it is put to its intended use? | | Yes  No | |
| 1. Has your country established a mechanism for monitoring potential effects of LMOs released into the environment? | | Yes  No | |
| 1. Does your country have the necessary infrastructure (e.g. laboratory facilities) for monitoring or managing LMOs? | | Yes  No | |
| 1. Here you may provide further details on the implementation of Articles 15 and 16 in your country:   [ Type your text here ] | | | |
| **Article 17 – Unintentional transboundary movements[[14]](#footnote-14) and emergency measures** | | | |
| 1. Has your country established measures to notify affected or potentially affected States, the Biosafety Clearing-House and, where appropriate, relevant international organizations in case of a release under its jurisdiction that leads, or may lead, to an unintentional transboundary movement of a LMO that is likely to have significant adverse effects? | | Yes  No | |
| 1. In the current reporting period, how many releases of LMOs occurred under your country’s jurisdiction that led, or may have led, to an unintentional transboundary movement? | | None  1 to 4  5 to 9  10 or more | |
| 1. If you answered *under question 86* that a *release occurred*, has your country notified affected or potentially affected States, the Biosafety Clearing-House and, where appropriate, relevant international organizations? | | Yes, always  In some cases only  No | |
| 1. Does your country have the capacity to take appropriate response measures in response to unintentional transboundary movements? | | Yes  No | |
| 1. In the current reporting period, how many times has your country become aware of an unintentional transboundary movement into its territory? | | None  1 to 4  5 to 9  10 or more | |
| 1. Here you may provide further details on the implementation of Article 17 in your country:   [ Type your text here ] | | | |
| **Article 18 – Handling, transport, packaging and identification** | | | |
| 1. Has your country taken measures to require that *LMOs that are subject to transboundary movement* are handled, packaged and transported under conditions of safety, taking into account relevant international rules and standards? | | Yes  No | |
| 1. Has your country taken measures to require that documentation accompanying LMOs-FFP, *in cases* *where the identity of the LMOs is not known,* clearly identifies that they *may contain LMOs* and are not intended for intentional introduction into the environment, as well as a contact point for further information? | | Yes  No | |
| 1. Has your country taken measures to require that documentation accompanying LMOs-FFP, *in cases where the identity of the LMOs is known*, clearly identifies that they *contain LMOs* and are not intended for intentional introduction into the environment, as well as a contact point for further information? | | Yes  No | |
| 1. If you answered *Yes* to question(s) 91, 92 and/or 93, what type of documentation does your country require for the identification of LMOs-FFP? | | Existing types of documentation  A stand-alone document  Existing or a stand-alone document | |
| 1. Has your country taken measures to require that documentation accompanying *LMOs that are destined for contained use* clearly identifies them as *LMOs* and specifies any requirements for the safe handling, storage, transport and use, the contact point for further information, including the name and address of the individual and institution to whom the LMO are consigned? | | Yes  No | |
| 1. If you answered *Yes* to question 95, what type of documentation does your country require for the identification of LMOs that are destined for contained use? | | Existing types of documentation  A stand-alone document  Existing or a stand-alone document | |
| 1. Has your country taken measures to require that documentation accompanying *LMOs that are intended for intentional introduction into the environment of the Party of import*, clearly identifies them as *living modified organisms*; specifies the identity and relevant traits and/or characteristics, any requirements for the safe handling, storage, transport and use, the contact point for further information and, as appropriate, the name and address of the importer and exporter; and contains a declaration that the movement is in conformity with the requirements of this Protocol applicable to the exporter? | | Yes  No | |
| 1. If you answered *Yes* to question 97, what type of documentation does your country require for the identification of LMOs that are intended for intentional introduction into the environment? | | Existing types of documentation  A stand-alone document  Existing or a stand-alone document | |
| 1. Does your country have available any guidance for the purpose of ensuring the safe handling, transport, and packaging of living modified organisms? | | Yes  No | |
| 1. Does your country have the capacity to enforce the requirements of identification and documentation of LMOs? | | Yes  No | |
| 1. How many customs officers in your country have received training in the identification of LMOs? | | None  1 to 9  10 to 49  50 to 99  100 or more  *Is this number adequate:  Yes  No* | |
| 1. Has your country established procedures for the sampling and detection of LMOs? | | Yes  No | |
| 1. How many laboratory personnel in your country have received training in detection of LMOs? | | None  1 to 9  10 to 49  50 to 99  100 or more  *Is this number adequate:  Yes  No* | |
| 1. Does your country have reliable access to laboratory facilities for the detection of LMOs? | | Yes  No | |
| 1. How many laboratories in your country are certified for LMO detection? | | None  1 to 4  5 to 9  10 to 49  50 or more | |
| 1. If you answered *under question 105* that *certified laboratories exist in your country*, how many of them are currently operating in the detection of LMOs? | | None  1 to 4  5 to 9  10 to 49  50 or more | |
| 1. Here you may provide further details on the implementation of Article 18 in your country:   [ Type your text here ] | | | |
| **Article 19 – Competent National Authorities and National Focal Points** | | | |
| 1. In case your country has designated more than one competent national authority, has your country established a mechanism for the coordination of their actions prior to taking decisions regarding LMOs? | | Yes  No  Not applicable (no competent national authority was designated) | |
| 1. Has your country established adequate institutional capacity to enable the competent national authority(ies) to perform the administrative functions required by the Cartagena Protocol on Biosafety? | | Yes  No | |
| 1. Has your country undertaken initiatives to strengthen collaboration among national focal points, competent national authority(ies) and other institutions on biosafety-related matters? | | Yes: [Please specify]  No | |
| 1. Here you may provide further details on the implementation of Article 19 in your country:   [ Type your text here ] | | | |
| **Article 20 – Information Sharing and the Biosafety Clearing-House (BCH)** | | | |
| 1. Please provide an overview of the status of the mandatory information provided by your country to the BCH by specifying for each category of information whether it is available and whether it has been submitted to the BCH. | | | |
| 1. Existing legislation, regulations and guidelines for implementing the Protocol, as well as information required by Parties for the advance informed agreement procedure (Article 20, paragraph 3 (a)) | | Information available and in the BCH  Information available but not in the BCH  Information available but only partially available in the BCH  Information not available | |
| 1. Legislation, regulations and guidelines applicable to the import of LMOs intended for direct use as food or feed, or for processing (Article 11, paragraph 5) | | Information available and in the BCH  Information available but not in the BCH  Information available but only partially available in the BCH  Information not available | |
| 1. Bilateral, multilateral and regional agreements and arrangements (Article 14, paragraph 2, and Article 20, paragraph 3 (b)) | | Information available and in the BCH  Information available but not in the BCH  Information available but only partially available in the BCH  Information not available | |
| 1. Contact details for competent national authorities (Article 19, paragraphs 2 and 3), national focal points (Article 19, paragraphs 1 and 3), and emergency contacts (Article 17, paragraph 3 (e)) | | Information available and in the BCH  Information available but not in the BCH  Information available but only partially available in the BCH  Information not available | |
| 1. Decisions by a Party regarding transit of LMOs (Article 6, paragraph 1) | | Information available and in the BCH  Information available but not in the BCH  Information available but only partially available in the BCH  Information not available | |
| 1. Decisions by a Party regarding import of LMOs for contained use (Article 6, paragraph 2) | | Information available and in the BCH  Information available but not in the BCH  Information available but only partially available in the BCH  Information not available | |
| 1. Notifications regarding the release under your country’s jurisdiction that leads, or may lead, to an unintentional transboundary movement of a LMO that is likely to have significant adverse effects on biological diversity (Article 17, paragraph 1) | | Information available and in the BCH  Information available but not in the BCH  Information available but only partially available in the BCH  Information not available | |
| 1. Information concerning cases of illegal transboundary movements of LMOs (Article 25, paragraph 3) | | Information available and in the BCH  Information available but not in the BCH  Information available but only partially available in the BCH  Information not available | |
| 1. Decisions regarding the importation of LMOs for intentional introduction into the environment (Article 10, paragraph 3) | | Information available and in the BCH  Information available but not in the BCH  Information available but only partially available in the BCH  Information not available | |
| 1. Information on the application of domestic regulations to specific imports of LMOs (Article 14, paragraph 4) | | Information available and in the BCH  Information available but not in the BCH  Information available but only partially available in the BCH  Information not available | |
| 1. Decisions regarding the domestic use of LMOs that may be subject to transboundary movement for direct use as food or feed, or for processing (Article 11, paragraph 1) | | Information available and in the BCH  Information available but not in the BCH  Information available but only partially available in the BCH  Information not available | |
| 1. Decisions regarding the import of LMOs intended for direct use as food or feed, or for processing that are taken under domestic regulatory frameworks (Article 11, paragraph 4) or in accordance with annex III (Article 11, paragraph 6) | | Information available and in the BCH  Information available but not in the BCH  Information available but only partially available in the BCH  Information not available | |
| 1. Declarations regarding the framework to be used for LMOs intended for direct use as food or feed, or for processing (Article 11, paragraph 6) | | Information available and in the BCH  Information available but not in the BCH  Information available but only partially available in the BCH  Information not available | |
| 1. Review and change of decisions regarding intentional transboundary movements of LMOs (Article 12, paragraph 1) | | Information available and in the BCH  Information available but not in the BCH  Information available but only partially available in the BCH  Information not available | |
| 1. Cases where intentional transboundary movement may take place at the same time as the movement is notified to the Party of import (Article 13, paragraph 1 (a)) | | Information available and in the BCH  Information available but not in the BCH  Information available but only partially available in the BCH  Information not available | |
| 1. LMOs granted exemption status by each Party (Article 13, paragraph 1 (b)) | | Information available and in the BCH  Information available but not in the BCH  Information available but only partially available in the BCH  Information not available | |
| 1. Summaries of risk assessments or environmental reviews of LMOs generated by regulatory processes and relevant information regarding products thereof (Article 20, paragraph 3 (c)) | | Information available and in the BCH  Information available but not in the BCH  Information available but only partially available in the BCH  Information not available | |
| 1. Please provide a brief explanation if you answered that the information is available *but not in the BCH* or *only partially available in the BCH* to any item under question 112:   [ Type your text here ] | | | |
| 1. Has your country established a mechanism for strengthening the capacity of the BCH National Focal Point to perform its administrative functions? | | Yes  No | |
| 1. Has your country established a mechanism for the coordination among the BCH National Focal Point, the Cartagena Protocol Focal Point, and the competent national authority(ies) for making information available to the BCH? | | Yes  No | |
| 1. Does your country use the information available in the BCH in its decision making processes on LMOs? | | Yes, always  Yes, in some cases  No  Not applicable (no decisions were taken) | |
| 1. Has your country experienced difficulties accessing or using the BCH? | | Yes: [Please specify]  No | |
| 1. In the reporting period, how many biosafety-related events (e.g. seminars, workshops, press conferences, educational events) has your country organized? | | None  1 to 4  5 to 9  10 to 24  25 or more | |
| 1. In the reporting period, how many biosafety-related publications has your country published? | | None  1 to 9  10 to 49  50 to 99  100 or more | |
| 1. Here you may provide further details on the implementation of Article 20 in your country:   [ Type your text here ] | | | |

|  |  |
| --- | --- |
| **Article 21 – Confidential information** | |
| 1. Has your country established procedures to protect confidential information received under the Protocol? | Yes  No |
| 1. Does your country allow the notifier to identify information that is to be treated as confidential? | Yes, always  In some cases only  No |
| 1. Here you may provide further details on the implementation of Article 21 in your country:   [ Type your text here ] | |
| **Article 22 – Capacity-building** | |
| 1. Does your country have predictable and reliable funding for building capacity for the effective implementation of the Protocol? | Yes  No |
| 1. Has your country received external support or benefited from collaborative activities with other Parties in the development and/or strengthening of human resources and institutional capacities in biosafety? | Yes  No |
| 1. If you answered *Yes* to question 125, how were these resources made available? | Bilateral channels  Regional channels  Multilateral channels |
| 1. Has your country provided support to other Parties in the development and/or strengthening of human resources and institutional capacities in biosafety? | Yes  No |
| 1. If you answered *Yes* to question 127, how were these resources made available? | Bilateral channels  Regional channels  Multilateral channels |
| 1. In the reporting period, has your country initiated a process to access GEF funds for building capacity in biosafety? | Yes: [Please specify]  No |
| 1. If you answered *Yes* to question 129, how would you characterize the process? | Very easy  Easy  Average  Difficult  Very difficult |
| 1. In the current reporting period, has your country undertaken activities for the development and/or strengthening of human resources and institutional capacities in biosafety? | Yes  No |
| 1. If you answered *Yes* to question 131, in which of the following areas were these activities undertaken (select all that apply)? | Institutional capacity and human resources  Integration of biosafety in cross-sectoral and sectoral legislation, policies and institutions (mainstreaming biosafety)  Risk assessment and other scientific and technical expertise  Risk management  Public awareness, participation and education in biosafety  Information exchange and data management including participation in the Biosafety Clearing-House  Scientific, technical and institutional collaboration at subregional, regional and international levels  Technology transfer  Identification of LMOs, including their detection  Socio-economic considerations  Implementation of the documentation requirements under Article 18.2 of the Protocol  Handling of confidential information  Measures to address unintentional and/or illegal transboundary movements of LMOs  Scientific biosafety research relating to LMOs  Taking into account risks to human health  Liability and redress  Other: [Please specify] |
| 1. In the current reporting period, has your country carried out a capacity-building needs assessment? | Yes  No |
| 1. Does your country still have capacity-building needs? | Yes  No |
| 1. If you answered *Yes* to question 134, which of the following areas still need capacity-building (select all that apply)? | Institutional capacity and human resources  Integration of biosafety in cross-sectoral and sectoral legislation, policies and institutions (mainstreaming biosafety)  Risk assessment and other scientific and technical expertise  Risk management  Public awareness, participation and education in biosafety  Information exchange and data management including participation in the Biosafety Clearing-House  Scientific, technical and institutional collaboration at subregional, regional and international levels  Technology transfer  Sampling, detection and identification of LMOs  Socio-economic considerations  Implementation of the documentation requirements for handling, transport, packaging and identification  Handling of confidential information  Measures to address unintentional and/or illegal transboundary movements of LMOs  Scientific biosafety research relating to LMOs  Taking into account risks to human health  Liability and redress  Other: [Please specify] |
| 1. Has your country developed a capacity-building strategy or action plan? | Yes  No |
| 1. Does your country have in place a functional national mechanism for coordinating biosafety capacity-building initiatives? | Yes  No |
| 1. Here you may provide further details on the implementation of Article 22 in your country, including further details about your experience in accessing GEF funds:   [ Type your text here ] | |
| **Article 23 – Public awareness and participation** | |
| 1. Is biosafety public awareness, education and/or participation addressed in legislation or policy in your country? | Yes  No |
| 1. In the current reporting period, has your country cooperated with other States and international bodies in relation to public awareness, education and participation? | Yes: [Please specify]  No |
| 1. Has your country established a mechanism to ensure public access to information on LMOs? | Yes  No |
| 1. Does your country have in place a national communication strategy on biosafety? | Yes  No |
| 1. Does your country have any awareness and outreach programmes on biosafety? | Yes: [Please specify]  No |
| 1. Does your country currently have a national biosafety website? | Yes  No |
| 1. How many academic institutions in your country are offering biosafety education and training courses and programmes? | None  1 to 4  5 to 9  10 or more  *Is this number adequate:  Yes  No* |
| 1. How many educational materials and/or online modules on biosafety are available and accessible to the public in your country? | None  1 to 4  5 to 9  10 to 24  25 to 99  100 or more  *Is this number adequate:  Yes  No* |
| 1. Has your country established a mechanism to consult the public in the decision-making process regarding LMOs? | Yes  No |
| 1. Has your country informed the public about existing modalities for public participation in the decision-making process regarding LMOs? | Yes  No |
| 1. If you answered *Yes* to question 148, please indicate the modalities used to inform the public: | National websites  Newspapers  Forums  Mailing lists  Public hearings  Other: [Please specify] |
| 1. In the current reporting period, how many times has your country consulted the public in the decision-making process regarding LMOs? | None (decisions taken without consultation)  1 to 4  5 or more  Not applicable (no decisions were taken) |
| 1. Has your country informed the public about the means to access the Biosafety Clearing-House? | Yes  No |
| 1. Here you may provide further details on the implementation of Article 23 in your country:   [ Type your text here ] | |
| **Article 24 – Non-Parties** | |
| 1. Has your country entered into any bilateral, regional, or multilateral agreement with non-Parties regarding transboundary movements of LMOs? | Yes  No |
| 1. In the reporting period, has your country imported LMOs from a non-Party? | Yes  No |
| 1. In the reporting period, has your country exported LMOs to a non-Party? | Yes  No |
| 1. If you answered *Yes* to question 154 and/or 155, were the transboundary movements of LMOs consistent with the objective of the Cartagena Protocol on Biosafety? | Yes, always  In some cases only  No |
| 1. Here you may provide further details on the implementation of Article 24 in your country:   [ Type your text here ] | |
| **Article 25 – Illegal transboundary movements[[15]](#footnote-15)** | |
| 1. Has your country adopted domestic measures aimed at preventing and/or penalizing transboundary movements of LMOs carried out in contravention of its domestic measures to implement this Protocol? | Yes  No |
| 1. In the current reporting period, how many cases of illegal transboundary movements of LMOs has your country become aware of? | None  1 to 4  5 to 9  10 or more |
| 1. If you indicated *under question 159* that *your country became aware of cases of illegal transboundary movements*, has the origin of the LMO(s) been established? | Yes  Yes, some cases  No |
| 1. Here you may provide further details on the implementation of Article 25 in your country:   [ Type your text here ] | |
| **Article 26 – Socio-economic considerations** | |
| 1. Does your country have any specific approaches or requirements that facilitate how socio-economic considerations should be taken into account in LMO decision making? | Yes  No |
| 1. In the reporting period, have socio-economic considerations arising from the impact of LMOs been taken into account in decision-making? | Yes, always  In some cases only  No  Not applicable (no decisions were taken) |
| 1. How many peer-reviewed published materials has your country used for the purpose of elaborating or determining national actions with regard to socio-economic considerations? | None  1 to 4  5 to 9  10 to 49  50 or more  *Is this number adequate:  Yes  No* |
| 1. Has your country cooperated with other Parties on research and information exchange on any socio-economic impacts of LMOs? | Yes  No |
| 1. Here you may provide further details on the implementation of Article 26 in your country:   [ Type your text here ] | |
| **Article 27 – Liability and Redress** | |
| 1. Is your country a Party to the Nagoya-Kuala Lumpur Supplementary Protocol on Liability and Redress? | Yes  No |
| 1. If you answered *No* to question 167, is there any national process in place towards becoming a Party? | Yes  No |
| 1. Does your country have administrative or legal instruments that require response measures to be taken: | |
| a. In case of damage resulting from LMOs? | Yes  No |
| b. In case there is sufficient likelihood that damage will result if response measures are not taken? | Yes  No |
| 1. If you answered *Yes* to question 169a, do these instruments impose requirements on an operator (select all that apply)? | Yes, the operator must inform the competent authority of the damage  Yes, the operator must evaluate the damage  Yes, the operator must take response measures  Yes, other requirements: [Please specify]  No |
| 1. If you answered *Yes* to question 169b, do these instruments require the operator to take response measures to avoid damage? | Yes  No |
| 1. If you answered *Yes* to question 169a or 169b, do these instruments provide for a definition of ‘operator’? | Yes  No |
| 1. If you answered *Yes* to question 172, which of the following could be an ‘operator’ (select all that apply)? | Permit holder  Person who placed the LMO on the market  Developer  Producer  Notifier  Exporter  Importer  Carrier  Supplier  Other: [Please specify] |
| 1. Has a competent authority been identified for carrying out the functions set out in the Supplementary Protocol? | Yes: [Please specify]  No |
| 1. If you answered *Yes* to question 174, what measures may the competent authority take (select all that apply)? | Identify the operator that caused the damage  Evaluate the damage  Determine response measures to be taken by operator  Implement response measures  Recover costs and expenses of the evaluation of the damage and the implementation of any response measures from the operator  Other: [Please specify] |
| 1. Does your country have measures in place to provide for financial security for damage resulting from LMOs? | Yes  No |
| 1. If you answered *Yes* to question 176, what type of financial security measures are in place (select all that apply)? | Requirement to provide evidence for secure source of funding  Mandatory insurance  Government schemes, including funds  Other: [Please specify] |
| 1. Does your country provide for rules and procedures on civil liability that address damage resulting from LMOs or has such damage been recognized in court rulings (select all that apply)? | Yes, in a civil liability instrument  Yes, in court rulings  Yes, in other instruments: [Please specify]  No |
| 1. Have there been any occurrences of damage resulting from LMOs in your country? | Yes: [Please specify]  No |
| 1. If you answered *Yes* to question 179, have response measures been taken? | Yes: [Please specify]  No |
| 1. Here you may provide further details on any activities undertaken in your country towards the implementation of the Nagoya-Kuala Lumpur Supplementary Protocol on Liability and Redress:   [ Type your text here ] | |
| |  | | --- | | **Article 28 – Financial Mechanism and Resources** | | |
| 1. In the reporting period, how much funding (in the equivalent of US dollars) has your country mobilized to support implementation of the Cartagena Protocol beyond the regular national budgetary allocation? | Nothing  1 to 4,999 USD  5,000 to 49,999 USD  50,000 to 99,999 USD  100,000 to 499,000 USD  500,000 USD or more |
| **Article 33 – Monitoring and reporting**  *Article 33 requires Parties to monitor the implementation of its obligations under the Cartagena Protocol and to report to the COP-MOP on measures taken to implement the Cartagena Protocol* | |
| 1. Does your country have in place a system to monitor and enforce the implementation of the Cartagena Protocol? | Yes  No |
| **Other information** | |
| 1. Please use this field to provide any other information on issues related to national implementation of the Protocol, including any obstacles or impediments encountered.   [ Type your text here ] | |
| **Comments on reporting format** | |
| 1. Please use this field to provide any other information on difficulties that you have encountered in filling in this report.   [ Type your text here ] | |

\_\_\_\_\_\_\_\_\_\_

1. \* [CBD/SBI/2/1](https://www.cbd.int/doc/c/6ce5/878e/5ffa49887c20c19961fe040a/sbi-02-01-en.pdf). [↑](#footnote-ref-1)
2. The Strategic Plan for the Cartagena Protocol on Biosafety for the period 2011-2020 is available online at <http://bch.cbd.int/protocol/issues/cpb_stplan_txt.shtml>. [↑](#footnote-ref-2)
3. In decision [BS-VII/3](https://www.cbd.int/doc/decisions/mop-08/mop-08-dec-03-en.pdf), the Conference of the Parties serving as the meeting of the Parties to the Cartagena Protocol decided to combine the two processes. [↑](#footnote-ref-3)
4. In its decision BS-VI/15, the Conference of the Parties serving as the meeting of the Parties to the Cartagena Protocol decided that the data and information contained in the analysis undertaken in the context of the second assessment and review of the effectiveness of the Protocol would form the baseline for measuring progress in implementing the Protocol, in particular the subsequent evaluation of the effectiveness of the Protocol and the mid-term evaluation of the implementation of the Strategic Plan. [↑](#footnote-ref-4)
5. Article 13 of the Supplementary Protocol requires that the Conference of the Parties serving as the meeting of the Parties to the Cartagena Protocol undertake a review of the effectiveness of the Supplementary Protocol five years after its entry into force and every five years thereafter, provided that information requiring such a review has been made available by Parties. [↑](#footnote-ref-5)
6. One hundred and five Parties had submitted their third national reports at the time when the analysis was done. [↑](#footnote-ref-6)
7. See decision [decision BS-VI/15](http://bch.cbd.int/protocol/decisions/?decisionID=13248). [↑](#footnote-ref-7)
8. The data used to carry out the analysis can be viewed in the National Report Analyzer, available at <http://bch.cbd.int/database/reports/analyzer>. [↑](#footnote-ref-8)
9. The input of the Compliance Committee is summarized in document UNEP/CBD/SBI/1/INF/34. [↑](#footnote-ref-9)
10. As document UNEP/CBD/BS/LG‑CB/11/2. [↑](#footnote-ref-10)
11. The contribution of the Liaison Group is summarized in document UNEP/CBD/SBI/1/INF/35. [↑](#footnote-ref-11)
12. Decision [BS-V/16](https://bch.cbd.int/protocol/decisions/decision.shtml?decisionID=12329), annex I. [↑](#footnote-ref-12)
13. This document is a protected form in MS Word format to enable further processing of the information contained therein by the CBD Secretariat. Only text entries and checkboxes may be changed. Once you finish filling in the form, please save it and print this first page for signature. This form is also available in the BCH for electronic submission at: [LINK TO BE ADDED]

    **IMPORTANT: To facilitate the analysis of the information contained in this report, it is recommended that Parties submit the report online through the Biosafety Clearing-House or as an attachment to an e-mail in MS Word format, together with a scanned copy of the first signed page, to the Secretariat at:** [**secretariat@cbd.int**](mailto:secretariat@cbd.int)**.**

    **Please *do not* send this report via fax or postal mail or in electronic formats other than MS Word.** [↑](#footnote-ref-13)
14. In accordance with the operational definition adopted in decision CP VIII/16, “‘Unintentional transboundary movement’ is a transboundary movement of a living modified organism that has inadvertently crossed the national borders of a Party where the living modified organism was released, and the requirements of Article 17 of the Protocol apply to such transboundary movements only if the living modified organism involved is likely to have significant adverse effects on the conservation and sustainable use of biological diversity, taking also into account risks to human health, in the affected or potentially affected States.” [↑](#footnote-ref-14)
15. In accordance with the operational definition adopted in decision CP VIII/16, “‘Illegal transboundary movement’ is a transboundary movement of living modified organisms carried out in contravention of the domestic measures to implement the Protocol that have been adopted by the Party concerned”. [↑](#footnote-ref-15)